Clinical Research Details

Clinical Research

The ABCD-Gene Prospective Study

Study Description

This investigation will be a prospective cohort study conducted in a population of 500 patients with stable CAD undergoing elective PCI treated with standard of care clopidogrel. By integrating genetic data with clinical variables, patients will be stratified into 2 cohorts based on their ABCD-GENE score (using a cut-off of 10). Assessments to define HPR status and myocardial infarction/myocardial injury will be performed post-PCI. Data will be collected and then entered into a secure database.

Inclusion/Exclusion Criteria

Inclusion criteria:

  1. Stable CAD undergoing elective PCI;
  2. Male or females, Age ≥ 18 years old;
  3. Troponin negative before PCI*†;
  4. Background of aspirin therapy;

* Troponin negative will be defined as hs-cTn below the URL for the laboratory (Male < 22 ng/L; Female < 14 ng/L) or modestly positive hs-cTn (Male: 22-99 ng/L; Female: 14-99 ng/L) flat or decreasing from hour 0 to 3.

† If troponin is unknown before coronary angiography and no clinical signs of acute coronary syndrome is present, a troponin will not be collected as this is line with standard practice.

Exclusion criteria:

  1. Current presentation with myocardial infarction;
  2. On treatment with prasugrel or ticagrelor;
  3. Documented hypersensitivity to clopidogrel; 
  4. Use of an intravenous antiplatelet therapy (i.e., cangrelor or GPI) during PCI;
  5. Unable to provide written informed consent.

Open Enrollment

Contact Name: Andrea Burton
Contact Phone: (904) 244-5617
Contact Email: andrea.burton@jax.ufl.edu

Investigators


Francesco Franchi, M.B.Ch.B. (M.D.)
Medicine